BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19695142)

  • 1. Economic impact of a rotavirus vaccination program in Mexico.
    Constenla D; Velázquez FR; Rheingans RD; Antil L; Cervantes Y
    Rev Panam Salud Publica; 2009 Jun; 25(6):481-90. PubMed ID: 19695142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
    Patel HD; Roberts ET; Constenla DO
    Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of rotavirus vaccination programs in Taiwan.
    Chang WC; Yen C; Chi CL; Wu FT; Huang YC; Lin JS; Huang FC; Tate JE; Wu HS; Hsiung CA
    Vaccine; 2013 Nov; 31(46):5458-65. PubMed ID: 24060569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
    Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China.
    Liu N; Yen C; Fang ZY; Tate JE; Jiang B; Parashar UD; Zeng G; Duan ZJ
    Vaccine; 2012 Nov; 30(48):6940-5. PubMed ID: 22705174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries.
    Rheingans RD; Constenla D; Antil L; Innis BL; Breuer T
    Rev Panam Salud Publica; 2007 Apr; 21(4):205-16. PubMed ID: 17612464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
    Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
    Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of a rotavirus vaccine in Brazil.
    Constenla DO; Linhares AC; Rheingans RD; Antil LR; Waldman EA; da Silva LJ
    J Health Popul Nutr; 2008 Dec; 26(4):388-96. PubMed ID: 19069617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
    Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
    BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
    Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
    PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Potential cost effectiveness of a rotavirus vaccine in Chile].
    Constenla D; O'Ryan M; Navarrete MS; Antil L; Rheingans RD
    Rev Med Chil; 2006 Jun; 134(6):679-88. PubMed ID: 17130941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact and cost-effectiveness of rotavirus vaccination in Bangladesh.
    Pecenka C; Parashar U; Tate JE; Khan JAM; Groman D; Chacko S; Shamsuzzaman M; Clark A; Atherly D
    Vaccine; 2017 Jul; 35(32):3982-3987. PubMed ID: 28623028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Economic impact of rotavirus vaccination in Panama].
    Constenla D; Ortega-Barría E; Rheingans RD; Antil L; Sáez-Llorens X
    An Pediatr (Barc); 2008 Feb; 68(2):128-35. PubMed ID: 18341878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of rotavirus vaccination in Albania.
    Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
    Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran.
    Javanbakht M; Moradi-Lakeh M; Yaghoubi M; Esteghamati A; Mansour Ghanaie R; Mahmoudi S; Shamshiri AR; Zahraei SM; Baxter L; Shakerian S; Chaudhri I; Fleming JA; Munier A; Baradaran HR
    Vaccine; 2015 May; 33 Suppl 1():A192-200. PubMed ID: 25919160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.
    Milne RJ; Grimwood K
    Value Health; 2009 Sep; 12(6):888-98. PubMed ID: 19490550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of the economic impact of the antiretroviral vaccine in Venezuela].
    Constenla D; Pérez-Schael I; Rheingans RD; Antil L; Salas H; Yarzábal JP
    Rev Panam Salud Publica; 2006 Oct; 20(4):213-22. PubMed ID: 17316479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis.
    Diop A; Atherly D; Faye A; Lamine Sall F; Clark AD; Nadiel L; Yade B; Ndiaye M; Fafa Cissé M; Ba M
    Vaccine; 2015 May; 33 Suppl 1():A119-25. PubMed ID: 25919151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of childhood rotavirus vaccination in Taiwan.
    Wu CL; Yang YC; Huang LM; Chen KT
    Vaccine; 2009 Mar; 27(10):1492-9. PubMed ID: 19186200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study.
    Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY
    Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.